Patents by Inventor Christopher Graham Raphael Parsons

Christopher Graham Raphael Parsons has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220193035
    Abstract: Provided herein are methods of use of indole derivative compounds for reversal of amyloid ? toxicity in amyloid ?-associated diseases.
    Type: Application
    Filed: April 23, 2020
    Publication date: June 23, 2022
    Applicant: Galimedix Therapeutics, Inc.
    Inventors: Christopher Graham Raphael. Parsons (Deceased), Gerhard Rammes, Hermann Russ, Andrew L Pearlman
  • Patent number: 9717772
    Abstract: Methods for the prevention and treatment of ocular disorders, in particular glaucoma, through blocking the toxic effects of ?-amyloid (A?) derivatives, pharmaceutical compositions for effecting such prevention and interval treatment thereof.
    Type: Grant
    Filed: June 20, 2013
    Date of Patent: August 1, 2017
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Hermann Russ, Wojciech Danysz, Christopher Graham Raphael Parsons
  • Patent number: 8288549
    Abstract: The invention relates to quinoline derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are glycine B antagonists and are therefore useful for the control and prevention of various disorders, including neurological disorders.
    Type: Grant
    Filed: September 30, 2009
    Date of Patent: October 16, 2012
    Assignee: Merz Pharma GmbH & Co. KGaA
    Inventors: Markus Henrich, Angela Bauer, Jens Nagel, Meik Sladek, Christopher Graham Raphael Parsons, Wojciech Danysz, Valerjans Kauss, Jevgenijs Rozhkovs, Igors Starchenkovs, Dina Trifanova
  • Publication number: 20110212956
    Abstract: Substituted pyrazolopyrimidine derivatives of formula (I) wherein Y1, Y2, Y3, Y4 represent N or C—, whereby at least two of the groups Y1 to Y4 represent a carbon atom, R1 represents chloro or bromo, R2 to R7 represent e.g. hydrogen, methyl or ethyl; and R10 and R11 independently represent e.g. hydrogen or C1-C6alkyl, are potent mGluR5 modulators and are useful for the prevention of acute and chronic neurological disorders.
    Type: Application
    Filed: May 3, 2011
    Publication date: September 1, 2011
    Applicant: MERZ PHARMA GmbH & CO. KGaA
    Inventors: Wojciech Danysz, Andrzej Dekundy, Mirko Hechenberger, Markus Henrich, Claudia Jatzke, Jens Nagel, Christopher Graham Raphael Parsons, Tanja Weil, Juris Fotins, Aleksandrs Gutcaitas, Ivars Kalvinsh, Ronalds Zemribo, Valerjans Kauss
  • Publication number: 20110190342
    Abstract: The invention relates to quinoline derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are glycine B antagonists and are therefore useful for the control and prevention of various disorders, including neurological disorders.
    Type: Application
    Filed: September 30, 2009
    Publication date: August 4, 2011
    Inventors: Markus Henrich, Angela Bauer, Jens Nagel, Meik Sladek, Christopher Graham Raphael Parsons, Wojciech Danysz, Valerjans Kauss, Jevgenijs Rozhkovs, Igos Starchenkovs, Dina Trifanova
  • Patent number: 7985753
    Abstract: Substituted pyrazolopyrimidine derivatives of formula (I) wherein Y1, Y2, Y3, Y4 represent N or C—, whereby at least two of the groups Y1 to Y4 represent a carbon atom, R1 represents chloro or bromo, R2 to R7 represent e.g. hydrogen, methyl or ethyl; and R10 and R11 independently represent e.g. hydrogen or C1-C6alkyl, are potent mGluR5 modulators and are useful for the prevention of acute and chronic neurological disorders.
    Type: Grant
    Filed: August 3, 2007
    Date of Patent: July 26, 2011
    Assignee: MERZ PHARMA GmbH & Co. KGaA
    Inventors: Wojciech Danysz, Andrzej Dekundy, Mirko Hechenberger, Markus Henrich, Claudia Jatzke, Jens Nagel, Christopher Graham Raphael Parsons, Tanja Weil, Juris Fotins, Aleksandrs Gutcaits, Ivars Kalvinsh, Ronalds Zemribo, Valerjans Kauss
  • Patent number: 7947689
    Abstract: The invention relates to pyrazolopyrimidine derivatives of formula (I) wherein Y1, Y2 and Y3 independently are e.g. CR10, NH, S or O, whereby at least one of Y1, Y2 and Y3 represents CR10; R1 represents chloro or bromo; R2, R3, R4, R5, R6 and R7 represent e.g. hydrogen or C1-C6-alkyl, and R10 represents e.g. hydrogen, halogen or phenyl; which are potent mGluR5 modulators and are e.g. useful for the treatment of various neurological disorders.
    Type: Grant
    Filed: August 3, 2007
    Date of Patent: May 24, 2011
    Assignee: Merz Pharma GmbH & Co. KGaA
    Inventors: Wojciech Danysz, Andrzej Dekundy, Mirko Hechenberger, Markus Henrich, Claudia Jatzke, Jens Nagel, Christopher Graham Raphael Parsons, Tanja Weil, Juris Fotins, Aleksandrs Gutcaits, Ivars Kalvinsh, Ronalds Zemribo, Valerjans Kauss
  • Publication number: 20100298442
    Abstract: Certain 1-aminoalkylcyclohexanes are systematically-active 5HT3 and nicotinic receptor antagonists and are useful in the inhibition of progression of or alleviation of conditions resulting from disturbances of serotoninergic or nicotinergic transmission giving them a wide range of utility in the treatment of CNS-disorders. Pharmaceutical compositions thereof for such purpose and method of making same, as well as a method-of-treating conditions which are alleviated by the employment of a 5HT3 or neuronal nicotinic receptor antagonist.
    Type: Application
    Filed: July 26, 2010
    Publication date: November 25, 2010
    Applicant: MERZ PHARMA GmbH & CO. KGaA
    Inventors: Christopher Graham Raphael Parsons, Wojciech Danysz, Markus Gold, Ivars Kalvinsh, Valerjans Kauss, Aigars Jirgensons
  • Patent number: 7598384
    Abstract: The invention relates to tetrahydroquinolinone derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are group I mGluR antagonists and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: October 6, 2009
    Assignee: Merz Pharma GmbH & Co. KGAA
    Inventors: Aigars Jirgensons, Christopher Graham Raphael Parsons, Ieva Jaunzeme, Ivars Kalvinsh, Markus Henrich, Maksims Vanejevs, Tanja Weil, Valerjans Kauss, Wojciech Danysz
  • Patent number: 7550482
    Abstract: The invention relates to ethynyl-substituted tetrahydroquinolinone derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are group I mGluR modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.
    Type: Grant
    Filed: August 24, 2005
    Date of Patent: June 23, 2009
    Assignee: Merz Pharma GmbH & Co. KGAA
    Inventors: Valerjans Kauss, Ieva Jaunzeme, Aigars Jirgensons, Ivars Kalvinsh, Maksims Vanejevs, Markus Henrich, Wojciech Danysz, Claudia Jatzke, Christopher Graham Raphael Parsons, Tanja Weil
  • Publication number: 20090081259
    Abstract: The present invention relates to the treatment of individuals diagnosed with multiple sclerosis, emotional lability or pseudobulbar affect comprising administering to said individual an effective amount of a 1-aminocyclohexane derivative, namely memantine or neramexane.
    Type: Application
    Filed: August 5, 2008
    Publication date: March 26, 2009
    Applicant: MERZ PHARMA GMBH & CO. KGAA
    Inventors: Jeffrey Jonas, Allison Mann, Christopher Graham Raphael Parsons, Wojciech Danysz
  • Publication number: 20080039476
    Abstract: The invention relates to pyrazolopyrimidine derivatives of formula (I) wherein Y1, Y2 and Y3 independently are e.g. CR10, NH, S or O, whereby at least one of Y1, Y2 and Y3 represents CR10; R1 represents chloro or bromo; R2, R3, R4, R5, R6 and R7 represent e.g. hydrogen or C1-C6-alkyl, and R10 represents e.g. hydrogen, halogen or phenyl; which are potent mGluR5 modulators and are e.g. useful for the treatment of various neurological disorders.
    Type: Application
    Filed: August 3, 2007
    Publication date: February 14, 2008
    Applicant: MERZ PHARMA GMBH & CO. KGAA
    Inventors: Wojciech Danysz, Andrzej Dekundy, Mirko Hechenberger, Markus Henrich, Claudia Jatzke, Jens Nagel, Christopher Graham Raphael Parsons, Tanja Weil, Juris Fotins, Aleksandrs Gutcaits, Ivars Kalvinsh, Ronalds Zemribo, Valerjans Kauss
  • Publication number: 20070299113
    Abstract: The invention relates to imidazothiazole derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are group I mGluR modulators and are therefore useful for the control and prevention of various disorders, including acute and/or chronic neurological disorders.
    Type: Application
    Filed: June 22, 2007
    Publication date: December 27, 2007
    Applicant: MERZ PHARMA GMBH & CO. KGAA
    Inventors: Ivars Kalvinsh, Larisa Kaulina, Valerjans Kauss, Ronalds Zemribo, Wojciech Danysz, Markus Henrich, Christopher Graham Raphael Parsons, Tanja Weil, Elina Erdmane
  • Patent number: 7022729
    Abstract: Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexanes which are systemically-active as NMDA, 5HT3, and nicotinic receptor antagonists, pharmaceutical compositions comprising the same, method of preparation thereof, and method of treating CNS disorders which involve disturbances of glutamatergic, serotoninergic, and nicotinic transmission, treating immunomodulatory disorders, and antimalaria, antitrypanosomal, anti-Borna virus, anti-HSV and anti-Hepatitis C virus activity.
    Type: Grant
    Filed: March 21, 2003
    Date of Patent: April 4, 2006
    Assignee: Merz Pharma GmbH & Co. KGAA
    Inventors: Christopher Graham Raphael Parsons, Markus Henrich, Wojciech Danysz, Ivars Kalvinsh, Valerjans Kauss, Aigars Jirgensons, Markus Gold, Maksims Vanejevs
  • Patent number: 6828462
    Abstract: Unsaturated 1-Amino-alkylcyclohexane compounds which are systemically-active as NMDA, 5HT3, and nicotinic receptor antagonists, pharmaceutical compositions comprising the same, method of preparation thereof, and method of treating CNS disorders which involve disturbances of glutamatergic, serotoninergic, and nicotinic transmission, treating immunomodulatory disorders, and antimalaria, antitrypanosomal, anti-Borna virus, anti-HSV and anti-Hepatitis C virus activity.
    Type: Grant
    Filed: November 6, 2002
    Date of Patent: December 7, 2004
    Assignee: Merz Pharma GmbH & Co. KGAA
    Inventors: Markus Henrich, Wojciech Danysz, Christopher Graham Raphael Parsons, Ivars Kalvinsh, Valerjans Kauss, Aigars Jirgensons, Markus Gold
  • Publication number: 20040034055
    Abstract: Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexanes which are systemically-active as NMDA, 5HT3, and nicotinic receptor antagonists, pharmaceutical compositions comprising the same, method of preparation thereof, and method of treating CNS disorders which involve disturbances of glutamatergic, serotoninergic, and nicotinic transmission, treating immunomodulatory disorders, and antimalaria, antitrypanosomal, anti-Borna virus, anti-HSV and anti-Hepatitis C virus activity.
    Type: Application
    Filed: March 21, 2003
    Publication date: February 19, 2004
    Applicant: MERZ PHARMA GMBH & CO. KGAA
    Inventors: Christopher Graham Raphael Parsons, Markus Henrich, Wojciech Danysz, Ivars Kalvinsh, Valerjans Kauss, Aigars Jirgensons, Markus Gold, Maksims Vanejevs
  • Publication number: 20030166634
    Abstract: Unsaturated 1-Amino-alkylcyclohexane compounds which are systemically-active as NMDA, 5HT3, and nicotinic receptor antagonists, pharmaceutical compositions comprising the same, method of preparation thereof, and method of treating CNS disorders which involve disturbances of glutamatergic, serotoninergic, and nicotinic transmission, treating immunomodulatory disorders, and antimalaria, antitrypanosomal, anti-Borna virus, anti-HSV and anti-Hepatitis C virus activity.
    Type: Application
    Filed: November 6, 2002
    Publication date: September 4, 2003
    Inventors: Markus Henrich, Wojciech Danysz, Christopher Graham Raphael Parsons, Ivars Kalvinsh, Valerjans Kauss, Aigars Jirgensons, Markus Gold
  • Patent number: 6071966
    Abstract: Certain 1-aminoalkylcyclohexanes are systemically-active uncompetitive NMDA receptor antagonists having rapid blocking/unblocking kinetics and strong voltage-dependency and are therefore useful in the alleviation of conditions resulting from disturbances of glutamatergic transmission giving them a wide range of utility in the treatment of CNS disorders involving the same, as well as in non-NMDA indications, due to their immunomodulatory, antimalarial, anti-Borna virus, and anti-Hepatitis C activities and utilities. Pharmaceutical compositions thereof and a method-of-treating conditions which are alleviated by the employment of an NMDA receptor antagonist, as well as the aforementioned non-NMDA indications, and a method for the preparation of the active 1-aminoalkylcyclohexane compounds involved.
    Type: Grant
    Filed: August 27, 1998
    Date of Patent: June 6, 2000
    Assignee: Merz + Co. GmbH & Co.
    Inventors: Markus Gold, Wojciech Danysz, Christopher Graham Raphael Parsons, Ivars Kalvinsh, Valerjans Kauss, Aigars Jirgensons
  • Patent number: 6034134
    Abstract: Certain 1-aminoalkylcyclohexanes are systemically-active uncompetitive NMDA receptor antagonists having rapid blocking/unblocking kinetics and strong voltage-dependency and are therefore useful in the alleviation of conditions resulting from disturbances of glutamatergic transmission giving them a wide range of utility in the treatment of CNS disorders involving the same, as well as in non-NMDA indications, due to their immunomodulatory, antimalarial, anti-Borna virus, and anti-Hepatitis C activities and utilities. Pharmaceutical compositions thereof and a method-of-treating conditions which are alleviated by the employment of an NMDA receptor antagonist, as well as the aforementioned non-NMDA indications, and a method for the preparation of the active 1-aminoalkylcyclohexane compounds involved.
    Type: Grant
    Filed: August 27, 1998
    Date of Patent: March 7, 2000
    Assignee: Merz + Co. GmbH & Co.
    Inventors: Markus Gold, Wojciech Danysz, Christopher Graham Raphael Parsons, Ivars Kalvinsh, Valerjans Kauss, Aigars Jirgensons
  • Patent number: 5776935
    Abstract: Pyridyl-phtalazin diones having the following formula: ##STR1## wherein R1 and R2 are selected from the group consisting of hydrogen, halogen, and methoxy or wherein R1 and R2 together form methylenedioxy, and pharmaceutically-acceptable salts thereof, and pharmaceutical compositions containing an effective glycine.sub.B antagonistic amount thereof, are useful in combatting neurological disorders associated with excitotoxicity and malfunctioning of glutamatergic neurotransmission in a living animal, including a human, in need thereof.
    Type: Grant
    Filed: July 25, 1996
    Date of Patent: July 7, 1998
    Assignee: Merz & Co. GmbH & Co.
    Inventors: Wojciech Danysz, Markus Gold, Ivars Kalvinsh, Christopher Graham Raphael Parsons, Irene Piskunova, Eugene Rozhkov